See more : Milgrey Finance and Investments Limited (ZMILGFIN.BO) Income Statement Analysis – Financial Results
Complete financial analysis of 2seventy bio, Inc. (TSVT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 2seventy bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bellavista Resources Limited (BVR.AX) Income Statement Analysis – Financial Results
- IEH Corporation (IEHC) Income Statement Analysis – Financial Results
- Pascal Biosciences Inc. (PSCBF) Income Statement Analysis – Financial Results
- Sumitomo Mitsui Financial Group, Inc. (SMFNF) Income Statement Analysis – Financial Results
- American Vanguard Corporation (AVD) Income Statement Analysis – Financial Results
2seventy bio, Inc. (TSVT)
About 2seventy bio, Inc.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 100.39M | 91.50M | 54.52M | 248.12M | 44.30M | 54.58M |
| Cost of Revenue | 16.92M | 26.22M | 12.59M | 5.40M | 2.98M | 885.00K |
| Gross Profit | 83.47M | 65.28M | 41.93M | 242.73M | 41.32M | 53.69M |
| Gross Profit Ratio | 83.15% | 71.34% | 76.91% | 97.83% | 93.28% | 98.38% |
| Research & Development | 230.76M | 248.74M | 261.94M | 296.47M | 297.65M | 200.49M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 69.41M | 79.45M | 93.51M | 90.90M | 81.65M | 53.63M |
| Other Expenses | 20.91M | 6.06M | 21.65M | 18.06M | 20.13M | 19.16M |
| Operating Expenses | 321.08M | 328.19M | 355.44M | 387.36M | 379.29M | 254.12M |
| Cost & Expenses | 317.09M | 354.40M | 368.03M | 392.76M | 382.27M | 255.01M |
| Interest Income | 12.41M | 2.93M | 88.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.49M |
| Depreciation & Amortization | 10.29M | 11.53M | 16.40M | 13.19M | 12.59M | 13.35M |
| EBITDA | -206.42M | -251.38M | -297.16M | -131.45M | -329.19M | -187.08M |
| EBITDA Ratio | -205.62% | -274.49% | -574.21% | -45.70% | -728.37% | -307.66% |
| Operating Income | -216.70M | -262.91M | -313.51M | -144.64M | -337.97M | -203.43M |
| Operating Income Ratio | -215.87% | -287.34% | -575.01% | -58.29% | -762.99% | -372.72% |
| Total Other Income/Expenses | -867.00K | 8.76M | 21.30M | 24.52M | 17.38M | 3.68M |
| Income Before Tax | -217.57M | -254.15M | -292.21M | -120.11M | -320.59M | -199.75M |
| Income Before Tax Ratio | -216.73% | -277.77% | -535.95% | -48.41% | -723.75% | -365.98% |
| Income Tax Expense | 0.00 | -8.99K | -16.00M | 18.06M | 2.75M | 19.16M |
| Net Income | -217.57M | -254.14M | -276.21M | -138.17M | -323.34M | -199.75M |
| Net Income Ratio | -216.73% | -277.77% | -506.61% | -55.69% | -729.96% | -365.98% |
| EPS | -4.42 | -7.13 | -11.71 | -5.93 | -13.88 | -8.58 |
| EPS Diluted | -4.42 | -7.13 | -11.71 | -5.93 | -13.88 | -8.58 |
| Weighted Avg Shares Out | 49.28M | 35.64M | 23.59M | 23.29M | 23.29M | 23.29M |
| Weighted Avg Shares Out (Dil) | 49.28M | 35.64M | 23.59M | 23.29M | 23.29M | 23.29M |
Did 2seventy bio, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - TSVT
NEW YORK, NY / ACCESSWIRE / September 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
NEW YORK, NY / ACCESSWIRE / September 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ: TSVT). Such investors are advised to contact Danielle Peyton at [email protected]...
Bronstein, Gewirtz & Grossman, LLC Encourages 2seventy bio, Inc. (TSVT) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / September 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 2seventy bio, Inc. ("2seventy bio" or "the Company") (NASDAQ:TSVT). Investors who purchased 2seventy bio securities...
Levi & Korsinsky Investigates Possible Securities Fraud Violations by 2seventy bio, Inc. (TSVT)
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a...
TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 2seventy bio, Inc. (“2seventy bio” or “the Company”) (NASDAQ: TSVT). Investors who purchased 2seventy bio securities are...
TSVT ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of 2seventy bio, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
NEW YORK , Sept. 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ: TSVT).
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against 2seventy bio, Inc. (TSVT) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / September 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 2seventy bio, Inc. ("2seventy bio" or "the Company") (NASDAQ:TSVT). Investors who purchased 2seventy bio securities...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or...
TSVT ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by 2seventy bio, Inc.
NEW YORK, NY / ACCESSWIRE / September 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a...
Source: https://incomestatements.info
Category: Stock Reports